Drugs such as chemotherapeutics that require glutathione conjugation, like busulfan and cisplatin, may have their bioavailability and toxicity altered due to variations in MGST2 activity. This enzyme, prominently expressed in the liver, kidneys, and intestines, plays a key role in the detoxification process and thus, influences the pharmacokinetics of these drugs, affecting their efficacy and safety.